| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Swift Christopher | Chairman and CEO, Director | ONE HARTFORD PLAZA, HARTFORD | Anthony J. Salerno, Jr., Attorney-in-Fact | 04 Feb 2026 | 0001349356 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HIG | Common Stock | Options Exercise | $9,872,749 | +201,938 | +104% | $48.89 | 396,755 | 02 Feb 2026 | Direct | |
| transaction | HIG | Common Stock | Sale | $1,041,503 | -7,598 | -1.9% | $137.08 | 389,157 | 02 Feb 2026 | Direct | F1, F2 |
| transaction | HIG | Common Stock | Sale | $1,075,433 | -7,845 | -2% | $137.09 | 381,312 | 02 Feb 2026 | Direct | F1, F3 |
| transaction | HIG | Common Stock | Sale | $2,674,662 | -19,734 | -5.2% | $135.54 | 361,578 | 02 Feb 2026 | Direct | F1, F4 |
| transaction | HIG | Common Stock | Sale | $2,688,755 | -19,834 | -5.5% | $135.56 | 341,744 | 02 Feb 2026 | Direct | F1, F5 |
| transaction | HIG | Common Stock | Sale | $10,023,056 | -73,390 | -21% | $136.57 | 268,354 | 02 Feb 2026 | Direct | F1, F6 |
| transaction | HIG | Common Stock | Sale | $10,043,529 | -73,537 | -27% | $136.58 | 194,817 | 02 Feb 2026 | Direct | F1, F6 |
| holding | HIG | Common Stock | 40,003 | 02 Feb 2026 | By Spouse | ||||||
| holding | HIG | Common Stock | 95,386 | 02 Feb 2026 | Swift Family Gift Trust | ||||||
| holding | HIG | Common Stock | 60,865 | 02 Feb 2026 | Swift Family Legacy Trust |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HIG | Stock Option | Options Exercise | $0 | -201,938 | -67% | $0.000000 | 100,970 | 02 Feb 2026 | Common Stock | 201,938 | $48.89 | Direct | F7 |
| holding | HIG | Stock Option | 352,263 | 02 Feb 2026 | Common Stock | 352,263 | $49.01 | Direct | F8 | |||||
| holding | HIG | Stock Option | 310,820 | 02 Feb 2026 | Common Stock | 310,820 | $51.87 | Direct | F9 | |||||
| holding | HIG | Stock Option | 284,819 | 02 Feb 2026 | Common Stock | 284,819 | $53.81 | Direct | F10 | |||||
| holding | HIG | Stock Option | 327,679 | 02 Feb 2026 | Common Stock | 327,679 | $55.27 | Direct | F11 | |||||
| holding | HIG | Stock Option | 301,932 | 02 Feb 2026 | Common Stock | 301,932 | $69.41 | Direct | F12 | |||||
| holding | HIG | Stock Option | 248,933 | 02 Feb 2026 | Common Stock | 248,933 | $78.28 | Direct | F13 | |||||
| holding | HIG | Stock Option | 116,414 | 02 Feb 2026 | Common Stock | 116,414 | $95.74 | Direct | F14 | |||||
| holding | HIG | Stock Option | 99,403 | 02 Feb 2026 | Common Stock | 99,403 | $116.41 | Direct | F15 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The transaction reported on this Form 4 was effected pursuant to a trading plan previously adopted by Mr. Swift on November 3, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The exercised options were granted to Mr. Swift in 2017 and are scheduled to expire on February 28, 2027. |
| F2 | Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $137.04 - $137.14 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F3 | Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $137.04 - $137.13 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F4 | Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $135.04 - $135.89 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F5 | Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $135.04 - $135.93 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F6 | Price reflected is the weighted average sale price for shares sold. The range of sales prices for the transactions reported was $136.04 - $137.03 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F7 | The options became fully exercisable on February 28, 2020, the third anniversary of the grant date. |
| F8 | The options became fully exercisable on February 26, 2022, the third anniversary of the grant date. |
| F9 | The options became fully exercisable on February 23, 2024, the third anniversary of the grant date. |
| F10 | The options became fully exercisable on February 27, 2021, the third anniversary of the grant date. |
| F11 | The options became fully exercisable on February 25, 2023, the third anniversary of the grant date. |
| F12 | The options became fully exercisable on February 23, 2025, the third anniversary of the grant date. |
| F13 | One-third of the options became exercisable on February 28, 2024, an additional one-third of the options became exercisable on February 28, 2025 and the remaining one-third of the options will become exercisable on February 28, 2026, the third anniversary of the grant date. |
| F14 | One-third of the options became exercisable on February 27, 2025, an additional one-third of the options will become exercisable on February 27, 2026 and the remaining one-third of the options will become exercisable on February 27, 2027, the third anniversary of the grant date. |
| F15 | One-third of the options will become exercisable on February 25, 2026, an additional one-third of the options will become exercisable on February 25, 2027 and the remaining one-third of the options will become exercisable on February 25, 2028, the third anniversary of the grant date. |